Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "drug interactions" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Role of healthcare professionals in drug-drug interactions and clinical interventions
    Autorzy:
    Siddiqui, Durr-e-Shahwar
    Powiązania:
    https://bibliotekanauki.pl/articles/2211406.pdf
    Data publikacji:
    2023-03-25
    Wydawca:
    Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
    Tematy:
    clinical interventions
    drug-drug interactions
    healthcare professionals
    Opis:
    Introduction and aim. Healthcare professionals including prescribers, pharmacists and nurses must have adequate knowledge of drug-drug interactions because they can cause toxicity, loss of efficacy, and side effects. This study was aimed to assess the respective roles of healthcare professionals in preventing drug-drug interactions by clinical interventions. Material and methods. This study was conducted at a Secondary Care Hospital of Pakistan in which total 1000 prescriptions were assessed for drug-drug interactions. Questionnaires and descriptive statistics were tools to assess the satisfaction of prescribers with pharmacists and their own prescribed medications before and after the clinical interventions. Modifications in medication therapies were done accordingly after the evaluation and acceptance of interventions. Results. The p-value was highly significant (p<0.05) which showed that the collaboration between healthcare professionals is necessary to avoid drug-drug interaction by clinical interventions. Acceptance rate of interventions was 77%. Clinical interventions are a useful tool in minimizing and preventing drug-drug interactions. The compliance of prescribers with their own prescribed medication regimens increased after clinical interventions. Conclusion. Prescribers, pharmacists and nurses have their respective roles in preventing drug-drug interactions and they must review the appropriateness of every medication order for clinical interventions.
    Źródło:
    European Journal of Clinical and Experimental Medicine; 2023, 1; 81-89
    2544-2406
    2544-1361
    Pojawia się w:
    European Journal of Clinical and Experimental Medicine
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Effects and time-kill assessment of amoxicillin used in combination with chloramphenicol against bacteria of clinical importance
    Autorzy:
    Olajuyigbe, Olufunmiso
    Coopoosamy, Roger
    Afolayan, Anthony
    Powiązania:
    https://bibliotekanauki.pl/articles/1038543.pdf
    Data publikacji:
    2017
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    drug-drug interactions
    fractional inhibitory concentrations
    multidrug resistance
    time-kill assessment
    Opis:
    With the emergence of multidrug-resistant organisms in an era when drug development faces challenges causing pharmaceutical companies to curtail or abandon research on anti-infective agents, the use of combined existing antimicrobial agents may be an alternative. This study evaluated the effects of combining amoxicillin and chloramphenicol, to which many bacteria have become resistant, in vitro against Gram positive and Gram negative bacteria by agar diffusion, checkerboard and time-kill assays. The test isolates were susceptible to amoxicillin with minimum inhibitory concentrations (MICs) ranging between 0.448 and 500 µg/ml and between 1.953 and 31.25 µg/ml for chloramphenicol. Upon combining these agents, there was a drastic reduction in their MICs indicating an increased antibacterial activity that showed synergistic interaction against all the bacteria. At the highest concentrations, the inhibition zones ranges were 20.33-38.33±0.58 µg/ml for amoxicillin, 27.67-37.67±0.58 µg/ml for chloramphenicol and 31.67-39.33±0.58 µg/ml for the combined agents. The fractional inhibitory concentration indices (FICIs) showed synergy ranging from 0.129 to 0.312 while FICIs for additive interaction were between 0.688 and 1.0. There was no antagonistic interaction. At the 1/2MICs of the combined antibiotics, all the tested bacteria, except for Klebsiella pneumoniae ATCC 4352, Proteus vulgaris CSIR 0030 and Enterococcus cloacae ATCC 13047 were eliminated before 24 h. At the MICs, all the tested bacteria were eliminated except Enterococcus cloacae ATCC 13047 which was almost totally eliminated. Post-antibiotic assessment after 48 h showed that all the cultures were sterile except for that of Enterococcus cloacae ATCC 13047. The lack of antagonism between these antibacterial agents in checkerboard and time-kill assays suggested that combining amoxicillin with chloramphenicol can provide an improved therapy in comparison to the use of each antibiotic individually. The study indicates the potential beneficial value of combining amoxicillin and chloramphenicol in the treatment of microbial infections in clinical settings.
    Źródło:
    Acta Biochimica Polonica; 2017, 64, 4; 609-613
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Farmakodynamiczne interakcje międzylekowe na oddziale intensywnej terapii – obserwacje jednoośrodkowe i przegląd piśmiennictwa
    Pharmacodynamic drug-drug interactions in the intensive care unit – single-center experience and literature review
    Autorzy:
    Łój, Piotr
    Olender, Aleksandra
    Ślęzak, Weronika
    Krzych, Łukasz
    Powiązania:
    https://bibliotekanauki.pl/articles/1035602.pdf
    Data publikacji:
    2018
    Wydawca:
    Śląski Uniwersytet Medyczny w Katowicach
    Tematy:
    interakcje międzylekowe
    farmakodynamika
    oddział intensywnej terapii
    drug-drug interactions
    pharmacodynamics
    intensive care unit
    Opis:
    INTRODUCTION: Drug-drug interactions (DDIs) constitute a serious health hazard in everyday clinical practice in the intensive care unit (ICU) setting. DDIs can be divided into pharmacokinetic and pharmacodynamic. We sought to investigate the quantity and quality of possible pharmacodynamic DDIs, and their possible side effects in ICU patients over a 12-month period. MATERIAL AND METHODS: This retrospective study covered data on the pharmacological treatment of 43 consecutive patients (11 F, 32 M) aged 62 ± 15 years, hospitalized between 01.2015 and 02.2016 in a mixed ICU. Pharmacokinetic DDIs were identified and graded. Only severe and clinically important DDIs were subjected to further analysis. RESULTS: The median baseline SAPS III was 53 (IQR 38–67) points. The median ICU stay was 12 (6–25) days. The subjects were treated with a median number of 22 (12–27) drugs. We identified 27 (16–41) possible DDIs per patient, including 3 (1–7) DDI of a severe grade. The total number of severe and clinically important pharmacodynamic pDDIs was 1189 and 320 of them were analyzed in details. Despite the gross number of those life-threatening conditions identified, no clinical sequelae of DDIs were recognized. CONCLUSIONS: DDIs as well as their effects are challenging for precise evaluation, especially due to the need for multidrug treatment in ICU patients. Despite the gross number of pDDIs in the ICU setting, further investigations are needed to examine their clinical sequelae.
    WSTĘP: Interakcje międzylekowe (DDIs) stanowią poważne zagrożenie dla zdrowia w codziennej praktyce klinicznej na oddziale intensywnej terapii (ICU). DDI dzielą się na farmakokinetyczne i farmakodynamiczne. Celem pracy była ocena częstości występowania i możliwych skutków interakcji farmakodynamicznych na ICU na przestrzeni 12 miesięcy. MATERIAŁ I METODY: Dokonano retrospektywnej analizy kart historii choroby 43 kolejnych pacjentów (11 kobiet, 32 mężczyzn) w wieku 62 ± 15 lat, hospitalizowanych między styczniem 2015 a lutym 2016 r. na wieloprofilowym ICU. Wyszukano i oceniono interakcje farmakodynamiczne. Analizie poddano tylko ciężkie i klinicznie istotne DDI. WYNIKI: Mediana w skali SAPS II wyniosła 53 (IQR 38–67), średni czas pobytu na oddziale 12 (6–12) dni, mediana liczby leków przyjmowanych przez pacjentów – 22 (12–27). Zidentyfikowano 27 (16–41) DDI w przeliczeniu na pacjenta, z czego 3 (1–7) stopnia ciężkiego. Całkowita liczba zidentyfikowanych farmakodynamicznych ciężkich i istotnych klinicznie DDI wynosiła 1189 z czego 320 poddano szczegółowej analizie. Nie badano i nie stwierdzono skutków klinicznych tych DDI. WNIOSKI: Identyfikacja DDI oraz ich skutków klinicznych jest wyzywaniem w praktyce lekarskiej, zwłaszcza przez wzgląd na wielolekowość u pacjentów na ICU. Pomimo znaczącej liczby pDDI w warunkach ICU, ocena ich efektów klinicznych wymaga dalszych analiz.
    Źródło:
    Annales Academiae Medicae Silesiensis; 2018, 72; 53-61
    1734-025X
    Pojawia się w:
    Annales Academiae Medicae Silesiensis
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    In Vitro approach for identification of a leading cytochrome P450 isoenzyme responsible for biotransformation of novel arylpiperazine drug candidates and their inhibition potency towards CYP3A4.
    Autorzy:
    Ulenberg, Szymon
    Belka, Mariusz
    Georgiev, Paweł
    Król, Marek
    Herold, Franciszek
    Bączek, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/895671.pdf
    Data publikacji:
    2020-02-29
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    cytochrome P-450
    drug-drug interactions
    isoform
    arylpiperazine
    CYP 3A4 inhibitor
    metabolic stability
    Opis:
    Presented article is a follow-up study of previous work, published in PLoS ONE in 2015 regarding metabolic stability of arylpiperazine derivatives, a very promising group of novel antidepressants. The aim of this study was to identify cytochrome P450 (CYP) isoforms that participate in the metabolism of some novel arylpiperazine derivatives developed by authors as well as their potency to inhibit reactions catalysed by identified lead metabolizing enzyme. Such studies allow to predict possible drug-drug interactions that might occur during co-administration of studied compounds with other drugs that are metabolized by identified enzyme. The compounds were incubated in vitro together with the isolated CYP isoforms. After the incubation, samples were analyzed by liquid chromatography coupled with mass spectrometry. The results showed main contribution of CYP3A4 isoform in biotransformation of the investigated derivatives. With CYP3A4 being the main CYP isoform responsible for the metabolism of arylpiperazine derivatives and at the same time being the main metabolizing enzyme for almost 50% of all drugs, a high chance of in vivo drug-drug interactions emerged. Therefore, IC50 values were also determined using testosterone hydroxylation as a probe reaction, specific for CYP3A4. The resulting values ranged from 6.13 to 15.85 µM, which places studied derivatives as moderate or weak inhibitors of CYP3A4. Those results, combined with conclusion that all of the arylpiperazine derivatives are also metabolized to some extent by other CYP isoforms (providing alternative metabolic pathways), result in conclusion that studied arylpiperazines might be safe for co-administration with other CYP3A4 substrates.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 1; 69-76
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies